Related Experiment Video
Updated: Apr 3, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Interferon therapy for chronic hepatitis B in children: an immunological perspective
Yinan Zhao1, Yige Wang1, Guoying Yu2
1Infectious Diseases Major, Qinghai University, Xining, China.
None:
Chronic hepatitis B (CHB) remains a significant global health issue, particularly in children, where the virus can lead to long-term hepatic damage and immune system dysregulation. Interferon (IFN) therapy, such as pegylated interferon (PEG-IFN), has served as a fundamental approach in the management of CHB by facilitating immune modulation and viral suppression. Nevertheless, the application of this treatment in children presents unique challenges, including heterogeneous immune responses, potential adverse effects, and constraints regarding long-term efficacy. This perspective discusses the immunological mechanisms associated with IFN therapy in pediatric CHB, emphasizing its potential to enhance immune-mediated clearance and suppress viral activity. We additionally examine the primary clinical challenges, including treatment resistance, adverse effects, and the necessity for personalized approaches to optimize therapeutic outcomes. Furthermore, this study examines prospective developments in IFN therapy, encompassing innovations in drug formulations, combination treatment strategies, and the implementation of personalized medicine approaches. Despite the challenges associated with IFN therapy, it continues to be a promising treatment modality. Furthermore, ongoing research into its combination with other immunomodulatory agents holds potential for developing more effective and sustainable management strategies for children with CHB.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism